A290650 Stock Overview
L&C Bio Co., Ltd operates as a research and development company in tissue regeneration medicine.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 5/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
L&C Bio Co., Ltd Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩20,100.00 |
| 52 Week High | ₩41,700.00 |
| 52 Week Low | ₩19,780.00 |
| Beta | 0.35 |
| 1 Month Change | -13.92% |
| 3 Month Change | -22.24% |
| 1 Year Change | -35.99% |
| 3 Year Change | -39.37% |
| 5 Year Change | 122.51% |
| Change since IPO | 123.75% |
Recent News & Updates
Recent updates
L&C Bio's (KOSDAQ:290650) Performance Raises Some Questions
Mar 27
Does L&C Bio (KOSDAQ:290650) Deserve A Spot On Your Watchlist?
Apr 20L&C Bio's (KOSDAQ:290650) Earnings Are Of Questionable Quality
Apr 01Is L&C Bio (KOSDAQ:290650) A Risky Investment?
Mar 02Announcing: L&C Bio (KOSDAQ:290650) Stock Increased An Energizing 163% In The Last Year
Feb 03What Is The Ownership Structure Like For L&C Bio Co., Ltd (KOSDAQ:290650)?
Jan 04Should You Be Excited About L&C Bio Co., Ltd's (KOSDAQ:290650) 16% Return On Equity?
Dec 08Shareholder Returns
| A290650 | KR Biotechs | KR Market | |
|---|---|---|---|
| 7D | -2.9% | -5.0% | -4.3% |
| 1Y | -36.0% | -3.5% | -1.0% |
Return vs Industry: A290650 underperformed the KR Biotechs industry which returned -2.6% over the past year.
Return vs Market: A290650 underperformed the KR Market which returned 0.6% over the past year.
Price Volatility
| A290650 volatility | |
|---|---|
| A290650 Average Weekly Movement | 4.7% |
| Biotechs Industry Average Movement | 8.0% |
| Market Average Movement | 5.2% |
| 10% most volatile stocks in KR Market | 12.0% |
| 10% least volatile stocks in KR Market | 2.4% |
Stable Share Price: A290650's share price has been volatile over the past 3 months.
Volatility Over Time: A290650's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2011 | 121 | Chul Lee Whan | www.lncbio.co.kr |
L&C Bio Co., Ltd operates as a research and development company in tissue regeneration medicine. It offers human tissue, medical device, and cosmetics products. The company was founded in 2011 and is headquartered in Seongnam-si, South Korea.
L&C Bio Co., Ltd Fundamentals Summary
| A290650 fundamental statistics | |
|---|---|
| Market cap | ₩455.97b |
| Earnings (TTM) | ₩48.36b |
| Revenue (TTM) | ₩68.87b |
9.4x
P/E Ratio6.6x
P/S RatioIs A290650 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A290650 income statement (TTM) | |
|---|---|
| Revenue | ₩68.87b |
| Cost of Revenue | ₩34.10b |
| Gross Profit | ₩34.77b |
| Other Expenses | -₩13.59b |
| Earnings | ₩48.36b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 2.13k |
| Gross Margin | 50.49% |
| Net Profit Margin | 70.22% |
| Debt/Equity Ratio | 50.9% |
How did A290650 perform over the long term?
See historical performance and comparison